Humacyte ( (HUMA) ) has provided an update.
On March 25, 2025, Humacyte, Inc. announced an underwritten public offering of 25,000,000 shares of its common stock at $2.00 per share, with an option for underwriters to purchase an additional 3,750,000 shares. The offering is expected to raise approximately $46.6 million, or $53.7 million if the option is fully exercised, and is set to close on March 27, 2025. The proceeds will be used to commercialize SYMVESS™ for vascular trauma, develop other pipeline products, and for general corporate purposes. This move is part of Humacyte’s strategy to advance its biotechnology platform and expand its market presence in bioengineered human tissues.
More about Humacyte
Humacyte, Inc. is a commercial-stage biotechnology company focused on developing universally implantable, bioengineered human tissues. The company specializes in creating acellular tissues and advanced tissue constructs for treating a variety of diseases and conditions. Humacyte’s initial product candidates include acellular tissue engineered vessels (ATEVs) for vascular trauma repair, hemodialysis access, and peripheral artery disease, with some products receiving FDA designations for advanced therapies.
YTD Price Performance: -44.50%
Average Trading Volume: 2,476,503
Technical Sentiment Signal: Buy
Current Market Cap: $427.2M
See more insights into HUMA stock on TipRanks’ Stock Analysis page.